CTLA4 and neoplasm: The 5-year survival of the majority of patients with metastatic malignant melanoma is poor despite success of new therapeutic strategies such as checkpoint inhibitory antibodies against CTLA-4 or PD-1 in a minority of patients.[30, 31] A major reason for tumor immune escape and therapy failure is the overwhelming immunosuppressive tumor microenvironment.